Innovation Management

Innovative approaches to the development of new and optimized drugs

Helmholtz Zentrum München focuses on supporting promising projects that are in the early stage of the value chain. These include projects in the field of drug discovery with innovative target structures and test systems to identify and develop effective and safe drugs for chronic, complex diseases. The portfolio of Helmholtz Zentrum München currently comprises development projects from the areas of diabetes, neurodegeneration, infectious diseases and cancer, such as:

  • New strategies to activate central signaling pathways in the regulation of the lipid and energy metabolism for the treatment of obesity and diabetes differentiation of embryonic stem cells into insulin-producing beta-cells
  • Identification of new drugs to combat neurodegenerative diseases
  • Identification of new HIV inhibitors through innovative test systems
  • Development of selective inhibitors of gene regulation in cancer
  • Inhibition of target structures in B-cell activation for the treatment of B-cell lymphoma
  • Development of bi-specific aptamers to combat B-cell lymphomas
  • New approaches to inhibit EBV-induced B-cell immortalization

We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Only cookies permitted that are required for the basic functionality of our websites.
Permit cookies that help us to analyse the page views and user behavior on our websites. We only use this information for improving our services.
Permit embedded content and cookies from third party providers. This setting enables the full use of our web services (e.g. displaying videos).
Please find more information in our privacy statement.

There you may also change your settings later.